2024/07/17 08:10:03 | |
---|---|
Price | |
0.2345 EUR | |
Difference | -1.88% (-0.00) |
ISIN | BE0974260896 |
Symbol | CYAD |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 11 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 0.2345 EUR (4,250) |
Ask (Ask size) | 0.2895 EUR (4,250) |
Open | 0.2345 EUR |
High | 0.2345 EUR |
Low | 0.2345 EUR |
Close (prev. day) | 0.239 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
Related Futures | - |
Related Options | - |
Date | Headline | Download | |
2024/07/12 | Global Equity Ratings | ||
2024/06/21 | Global Equity Ratings | ||
2024/06/14 | Global Equity Ratings | ||
2024/05/29 | Global Equity Ratings | ||
2024/04/26 | Global Equity Ratings |
2024/07/17 08:10:03 | |
---|---|
Price | |
0.2345 EUR | |
Difference | -1.88% (-0.00) |
ISIN | BE0974260896 |
Symbol | CYAD |
Exchange | Duesseldorf |
Currency | EUR |
Sector | Chemical / Pharmaceutical / Health |
Security type | Stock |
Market cap (m) | 11 EUR |
Benchmark | BEL 20 INDEX |
Bid (Bid size) | 0.2345 EUR (4,250) |
Ask (Ask size) | 0.2895 EUR (4,250) |
Open | 0.2345 EUR |
High | 0.2345 EUR |
Low | 0.2345 EUR |
Close (prev. day) | 0.239 EUR |
VWAP | - |
Volume (pcs) | 0 |
Trading volume | 0.00 |
Number of trades | 1 |
Last size | 0 |
6m | 1Y | 3Y | |
Perf (%) | -28.01% | -36.77% | -93.22% |
Perf (abs.) | -0.09 | -0.14 | -3.29 |
Beta | 0.42 | 0.28 | 0.59 |
Volatility | 46.46 | 123.58 | 150.77 |
Ø price 5 days | Ø volume 5 days (pcs.) | 0.2410 EUR (0) |
Ø price 30 days | Ø volume 30 days (pcs.) | 0.2605 EUR (0) |
Ø price 100 days | Ø volume 100 days (pcs.) | 0.2908 EUR (0) |
Ø price 250 days | Ø volume 250 days (pcs.) | 0.3878 EUR (0) |
YTD High | date | 0.4070 EUR (2024/01/29) |
YTD Low | date | 0.2385 EUR (2024/07/11) |
52 Weeks High | date | 1.1500 EUR (2023/09/04) |
52 Weeks Low | date | 0.2385 EUR (2024/07/11) |
Exchange | Date | Time | Price | Trading volume (mio.) | Number of trades |
Stuttgart | 2024/07/17 | 08:03 | 0.2355 EUR | 0.00 | 1 |
Munich | 2024/07/17 | 08:18 | 0.299 EUR | 0.00 | 1 |
London Stock Exchange | 2021/01/27 | 09:06 | 6.9303 EUR | 0.00 | 1 |
Frankfurt | 2024/07/17 | 08:07 | 0.2275 EUR | 0.00 | 1 |
FINRA other OTC Issues | 2024/07/08 | 18:39 | 0.25 USD | 0.00 | 1 |
Euronext Brussels | 2024/07/16 | 17:35 | 0.2675 EUR | 0.00 | 20 |
Duesseldorf | 2024/07/17 | 08:10 | 0.2345 EUR | 0.00 | 1 |
Berlin | 2024/07/17 | 08:19 | 0.2275 EUR | 0.00 | 1 |
CELYAD ONCOLOGY SA |
- - |
Axis Business Park, Rue André Dumont 9 - 1435 Mont-Saint-Guibert |
Telefon: +32-10-039-41-00 |
Fax: +32-10-039-41-41 |
E-mail: info@celyad.com |
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium. |
Georges Rawadi | Chairman of Managing Board |
An Phan | Member of Executive Committee |
David Georges | Member of Executive Committee |
Eytan Breman | Member of Executive Committee |
Hannes Iserentant | Member of Executive Committee |
Hilde Windels | Chairman of Supervisory Board |
Marina Udier | Member of Supervisory Board |
Ami Shah | Member of Supervisory Board |
Andrea Gothing | Member of Supervisory Board |
Dominic Piscitelli | Member of Supervisory Board |
John LiPuma | Member of Supervisory Board |
Jonathan James | Member of Supervisory Board |
Sage Mandel | Member of Supervisory Board |
Serge Goblet | Member of Supervisory Board |
Any information, material and services regarding financial instruments and securities provided by Česká spořitelna/Erste Group/ or any of its affiliates (collectively “Erste Group“) on this and any linked website hereafter (jointly the “Websites“) shall be exclusively to investors who are not subject to any legal sale or purchase restrictions.
By agreeing to this hereto, the visitor entering this Websites confirms that has read, understood and accepted this Information and the Disclaimer